Cardiac events in the setting of ofatumumab treatment: An association or A Co-incidence? Neuroimmunology Reports Khan, Hamna, Michelle Maynard, and Ahmed Z. Obeidat. "Cardiac events in the setting of ofatumumab treatment: An association or A Co-incidence?." Neuroimmunology Reports 6 (2024): 100228.
Date
12/01/2024Abstract
Background
Despite its rarity, concerns about cardiac complications could be linked to ofatumumab in line with its cardiac risks in non-MS treatments. Here, we provide a first-time report of two instances of acute myocardial events in women under 50 temporally associated with ofatumumab for the treatment of multiple sclerosis (MS). Both patients were also on stimulant medications, suggesting that clinicians should take caution when prescribing anti-CD20 agents to patients with cardiovascular risk factors or concomitant use of stimulants.
Discussion
Further research is needed to confirm and quantify the association between anti-CD20 agents in use in patients with cardiovascular risk factors on concomitant use of stimulants.
Author List
Hamna Khan, Michelle Maynard, Ahmed Z ObeidatAuthor
Ahmed Zayed Obeidat MD, PhD Associate Professor in the Neurology department at Medical College of WisconsinView Online
